SEARCH

SEARCH BY CITATION

REFERENCES

  • Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crino L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thurlimann B. 2008. Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 19: 420432.
  • Agarwal AK, Fryns JP, Auchus RJ, Garg A. 2003. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet 12: 19952001.
  • Arboleda G, Ramirez N, Arboleda H. 2007. The neonatal progeroid syndrome (Wiedemann–Rautenstrauch): A model for the study of human aging? Exp Gerontol 42: 939943.
  • Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, Garcia-Hernandez PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC. 2010. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 25: 404414.
  • Braddock SR, Ardinger HH, Yang CS, Paschal BM, Hall BD. 2010. Petty syndrome and Fontaine–Farriaux syndrome: Delineation of a single syndrome. Am J Med Genet Part A 152A: 17181723.
  • Burtner CR, Kennedy BK. 2010. Progeria syndromes and ageing: What is the connection? Nat Rev Mol Cell Biol 11: 567578.
  • Cheung A, Seeman E. 2010. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 363: 24732474.
  • Cunningham VJ, D'Apice MR, Licata N, Novelli G, Cundy T. 2010. Skeletal phenotype of mandibuloacral dysplasia associated with mutations in ZMPSTE24. Bone 47: 591597.
  • De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, Levy N. 2003. Lamin a truncation in Hutchinson–Gilford progeria. Science 300: 2055.
  • Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS. 2003. Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome. Nature 423: 293298.
  • Friedrich K, Lee L, Leistritz DF, Nurnberg G, Saha B, Hisama FM, Eyman DK, Lessel D, Nurnberg P, Li C, Garcia FVMJ, Kets CM, Schmidtke J, Cruz VT, Van den Akker PC, Boak J, Peter D, Compoginis G, Cefle K, Ozturk S, Lopez N, Wessel T, Poot M, Ippel PF, Groff-Kellermann B, Hoehn H, Martin GM, Kubisch C, Oshima J. 2010. WRN mutations in Werner syndrome patients: Genomic rearrangements, unusual intronic mutations and ethnic-specific alterations. Hum Genet 128: 103111.
  • Gordon LB, McCarten KM, Giobbie-Hurder A, Machan JT, Campbell SE, Berns SD, Kieran MW. 2007. Disease progression in Hutchinson–Gilford progeria syndrome: Impact on growth and development. Pediatrics 120: 824833.
  • Harper RP, Fung E. 2007. Resolution of bisphosphonate-associated osteonecrosis of the mandible: Possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 65: 573580.
  • Hennekam RC. 2006. Hutchinson–Gilford progeria syndrome: Review of the phenotype. Am J Med Genet Part A 140A: 26032624.
  • Kivuva EC, Parker MJ, Cohen MC, Wagner BE, Sobey G. 2008. De Barsy syndrome: A review of the phenotype. Clin Dysmorphol 17: 99107.
  • Kraemer KH, Patronas NJ, Schiffmann R, Brooks BP, Tamura D, DiGiovanna JJ. 2007. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: A complex genotype–phenotype relationship. Neuroscience 145: 13881396.
  • Lau AN, Adachi JD. 2009. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol 36: 18351837.
  • Lee SJ, Whitewood C, Murray KJ. 2010. Inherited multicentric osteolysis: Case report of three siblings treated with bisphosphonate. Pediatr Rheumatol Online J 8: 12.
  • Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon RO III, Gahl WA, Introne WJ. 2008. Phenotype and course of Hutchinson–Gilford progeria syndrome. N Engl J Med 358: 592604.
  • Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 14341441.
  • Osorio FG, Obaya AJ, Lopez-Otin C, Freije JM. 2009. Accelerated ageing: From mechanism to therapy through animal models. Transgenic Res 18: 715.
  • Pendas AM, Zhou Z, Cadinanos J, Freije JM, Wang J, Hultenby K, Astudillo A, Wernerson A, Rodriguez F, Tryggvason K, Lopez-Otin C. 2002. Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet 31: 9499.
  • Puente XS, Quesada V, Osorio FG, Cabanillas R, Cadinanos J, Fraile JM, Ordonez GR, Puente DA, Gutierrez-Fernandez A, Fanjul-Fernandez M, Levy N, Freije JM, Lopez-Otin C. 2011. Exome sequencing and functional analysis identifies BANF1 mutation as the cause of a hereditary progeroid syndrome. Am J Hum Genet 88: 650656.
  • Ramirez CL, Cadinanos J, Varela I, Freije JM, Lopez-Otin C. 2007. Human progeroid syndromes, aging and cancer: New genetic and epigenetic insights into old questions. Cell Mol Life Sci 64: 155170.
  • Shastry S, Simha V, Godbole K, Sbraccia P, Melancon S, Yajnik CS, Novelli G, Kroiss M, Garg A. 2010. A novel syndrome of mandibular hypoplasia, deafness, and progeroid features associated with lipodystrophy, undescended testes, and male hypogonadism. J Clin Endocrinol Metab 95: E192E197.
  • Tsiridis E, Morgan EF, Bancroft JM, Song M, Kain M, Gerstenfeld L, Einhorn TA, Bouxsein ML, Tornetta P III. 2007. Effects of OP-1 and PTH in a new experimental model for the study of metaphyseal bone healing. J Orthop Res 25: 11931203.
  • Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB. 2002. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30: 312321.
  • Varela I, Pereira S, Ugalde AP, Navarro CL, Suarez MF, Cau P, Cadinanos J, Osorio FG, Foray N, Cobo J, de Carlos F, Levy N, Freije JM, Lopez-Otin C. 2008. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 14: 767772.
  • Worman HJ, Fong LG, Muchir A, Young SG. 2009. Laminopathies and the long strange trip from basic cell biology to therapy. J Clin Invest 119: 18251836.